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1CEO, Diabetes Nation, High Lakes Health Care, Bend, OR 
2Professor, Primary Care Department, Touro University California College of Osteopathic Medicine, Vallejo, CA
INTRODUCTION
The sodium glucose co-transporter 2 (SGLT2) inhibitors are 
the first agents to address hyperglycemia by targeting the 
kidneys in patients with type 2 diabetes mellitus (T2DM). 
Three medications in this therapeutic class entered the U.S. 
market within 17 months — canagliflozin in March 2013, 
followed by dapagliflozin in January 2014, and empagliflozin 
in August 2014.1-3  SGLT2 inhibitors are included in the 2013 
treatment algorithm of the American Association of Clinical 
Endocrinologists (AACE),4  and in the 2015 American 
Diabetes Association (ADA) Standards of Medical Care.5 
To offer guidance on the place of SGLT2 inhibitors in 
osteopathic clinical practice, this review describes the 
mechanism of action of these agents and summarizes efficacy 
and safety data from phase 3 clinical trials with the three 
SGLT2 inhibitors available in the United States. 
ROLE OF THE KIDNEYS IN HYPERGLYCEMIA & DIABETES
The kidneys influence glucose homeostasis primarily by 
reabsorbing glucose from the glomerular filtrate.  In healthy 
individuals, virtually all of the filtered glucose is reabsorbed 
into the circulation.6  The majority of glucose reabsorption 
(about 90%) occurs through SGLT2, which is located almost 
exclusively in the proximal tubule.6 
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Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, control of which typically requires 
multiple therapies. Current guidelines suggest that, in addition to improving glycemic control, 
antihyperglycemic therapy should be chosen on the basis of its effects on body weight and the 
risk of hypoglycemia. The newest class of oral antihyperglycemic agents, the sodium glucose co-
transporter 2 (SGLT2) inhibitors, reduces renal glucose reabsorption and increases urinary glucose 
excretion via an insulin-independent mechanism of action. SGLT2 inhibitors have been shown 
to improve glycemic control and to reduce body weight and systolic blood pressure, and their 
use is associated with a low risk of hypoglycemia. This paper explains the mechanism of action 
of SGLT2 inhibitors and reviews published efficacy and safety data from phase 3 clinical trials 
and pooled analyses for the three SGLT2 inhibitors currently approved by the U.S. Food and Drug 
Administration for use in patients with T2DM: canagliflozin (Invokana®), dapagliflozin (Farxiga™), 
and empagliflozin (Jardiance®). Implications for clinical osteopathic practice are discussed.
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When the plasma glucose concentration exceeds 180 - 
200 mg/dL in healthy adults (the renal threshold),7, 8 the 
reabsorptive capacity of the kidneys is exceeded and glucose 
is excreted in the urine.6  In patients with diabetes, the renal 
threshold for glucose is increased by as much as 20%, to up 
to 240 mg/dL.8-10  This change is counterproductive because 
the hyper-reabsorption of glucose leads to maintenance or 
exacerbation of the hyperglycemic state, rather than spilling 
excess glucose into the urine.6,11 
SGLT2 INHIBITORS 
MECHANISM OF ACTION
Canagliflozin, dapagliflozin, and empagliflozin are all highly 
selective inhibitors of SGLT2.12-15  Inhibition of SGLT2 reduces 
renal glucose reabsorption and lowers the renal threshold for 
glucose reabsorption, leading to increased urinary glucose 
excretion (UGE) and reduction of hyperglycemia in patients 
with T2DM.12,16  UGE attributable to SGLT2 inhibition is 
approximately 80-120 g/day with canagliflozin 100 mg 
and 300 mg,17-20 approximately 70 g/day with dapagliflozin 
10 mg,21 and approximately 78 g/day with empagliflozin 
25 mg.22  In addition, canagliflozin 300mg has been shown 
to lower postprandial glucose excursion, likely because local 
concentrations of canagliflozin in the gut lumen may be 
sufficient to transiently inhibit intestinal SGLT1.23-25 As SGLT2 
inhibitors act independently of beta-cell function or insulin 
sensitivity,26 this class of medication can be used in all stages 
of diabetes.27, 28
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Small studies have reported an increase in endogenous 
glucose production (EGP) with SGLT2 inhibitors;23, 29, 30 
plasma glucose showed a net decrease despite elevated EGP. 
The mechanism of this phenomenon is currently unexplained, 
but elevated EGP may be a compensatory response to support 
normal plasma glucose levels in the presence of sustained 
UGE.23 
CLINICAL BENEFITS
A systematic review and meta-analysis of clinical trials 
comparing SGLT2 inhibitors with placebo (45 studies, 
n=11,232) or active comparator (13 studies, n=5,175) 
reported improved glycemic control, reduced body mass, and 
reduced blood pressure with SGLT2 inhibitor therapy.31  These 
effects have been confirmed by other published reviews.32-34 
Although glycated hemoglobin A (A1C) improved in all 
groups of patients, those with higher baseline A1C values 
generally experienced greater A1C reductions.30, 35-37
SAFETY
Side effects associated with the SGLT2 inhibitor class and 
its mechanism of action of increasing UGE include genital 
mycotic infections (GMIs), urinary tract infections (UTIs), 
osmotic diuresis-related events, and volume depletion.32 
When SGLT2 inhibitors are used as monotherapy, the risk 
of hypoglycemia is comparable to that of other classes of 
antihyperglycemic agents (AHA) that are not associated 
with hypoglycemia.31,  36  Rates of serious adverse events 
(AEs) range between 1.0% and 12.6%, and AEs resulting in 
discontinuation of therapy range between 0.9% and 9.9%.32
Glycemic lowering by SGLT2 inhibitors depends on 
glomerular filtration; therefore, efficacy may be reduced in 
patients with renal impairment.  The prescribing information 
for each SGLT2 inhibitor includes recommendations specific 
to patients with reduced renal function. Patients with 
estimated glomerular filtration rate (eGFR) ≥ 45 to < 60 mL/
min/1.73 m2 should receive only lower-dose canagliflozin (100 
mg), whereas empagliflozin 10 mg and 25 mg can be used in 
patients with eGFR ≥ 45 mL/min/1.73 m2.17, 22    Dapagliflozin 
is not indicated in this patient population.21  Canagliflozin 
and empagliflozin should not be initiated in individuals with 
an eGFR < 45 mL/min/1.73 m2.17, 22  Dapagliflozin should 
not be started in patients with eGFR < 60 mL/min/1.73 m2.21 
Renal function should be monitored and SGLT2 therapy 
discontinued if eGFR remains persistently below these 
levels (eGFR: < 45 mL/min/1.73 m2 for canagliflozin 
and empagli f lozin,  and < 60 mL/min/1.73 m2 for 
dapagliflozin).17, 21, 22 
EFFICACY AND SAFETY OF INDIVIDUAL U.S. FOOD 
AND DRUG ADMINISTRATION–APPROVED AGENTS 
CANAGLIFLOZIN:
EFFICACY AND CLINICAL BENEFITS
Table 1 (pages 12-17) summarizes the results of phase 3 trials 
of canagliflozin.35, 36, 38-44 Compared with placebo, canagliflozin 
100 mg and 300 mg significantly reduced A1C from baseline 
to 26 weeks when given as monotherapy, dual therapy (added 
to metformin), or triple therapy (added to metformin plus a 
sulfonylurea or metformin plus pioglitazone).35, 36, 40, 42 
When compared with glimepiride38 or sitagliptin40 as 
add-on therapy to metformin for 52 weeks, A1C reduction 
with canagliflozin 300 mg was superior to that of comparators, 
whereas A1C reduction with canagliflozin 100 mg was non-
inferior to comparators. In a study comparing canagliflozin 
300 mg with sitagliptin as add-on therapy to metformin plus 
a sulfonylurea, canagliflozin 300 mg produced A1C reduction 
superior to that of sitagliptin.41
As monotherapy, dual therapy (added to metformin), and 
triple therapy (added to metformin plus a sulfonylurea), 
canagliflozin 100 mg and 300 mg were associated with 
significantly greater reductions in body weight at 26 weeks 
compared with placebo.35, 36, 40 As dual therapy (added to 
metformin), canagliflozin at both doses was associated with 
significantly greater body weight reduction versus sitagliptin40 
or glimepiride at 52 weeks.38  As triple therapy (added to 
metformin plus a sulfonylurea), canagliflozin 300 mg was 
associated with significantly greater body weight reduction 
than sitagliptin at 52 weeks.41  Weight reduction early in 
canagliflozin treatment is likely, in part, attributable to fluid 
loss;45  however, over time, the reduction in body weight is 
mainly attributable to reduction in fat mass.38 
Compared with placebo, canagliflozin 100 mg and 300 
mg significantly reduced systolic blood pressure (SBP) as 
monotherapy and as dual therapy (added to metformin) at 
26 weeks,35,  40 and as dual therapy (added to metformin)40 and 
triple therapy (added tor metformin plus a sulfonylurea)41 
compared with sitagliptin at 52 weeks. As dual therapy (added 
to metformin), canagliflozin modestly reduced SBP at 52 
weeks compared with glimepiride, which was associated with 
a small increase.38  As triple therapy (added to metformin plus 
a sulfonylurea), canagliflozin was associated with numerical 
SBP reductions at 26 weeks.36
High-density lipoprotein cholesterol (HDL-C) significantly 
increased with canagliflozin 100 mg and 300 mg at 26 weeks as 
monotherapy35 and triple therapy,42 compared with placebo. In 
other studies, changes in HDL-C with canagliflozin were either 
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Efficacy and Safety of CANA in Randomized, Double-Blind Phase 3 Trials of Patients With Type 2 Diabetes Mellitus
Ref.
Efficacya











a  Least-squares mean change from baseline value (with standard error in parentheses where provided).
b  p<0.001 vs. PBO, difference vs. baseline.
c  p<0.01 vs. comparator or PBO, difference vs. baseline.
d  Non-inferior to comparator.
e  Superior to comparator. 
f  p<0.0001 vs. comparator, difference vs. baseline.
g  p<0.001 vs. comparator, difference vs. baseline.
 (CONTINUED)
EFFICACY AND CLINICAL BENEFITS - CANAGLIFLOZIN 
In older adults (aged 55-80 years), canagliflozin 100mg and 
300mg as add-on therapy to study participants’ current 
treatment regimens was associated with significant reductions 
from baseline in A1C, body weight, and SBP, and an increase 
in HDL-C relative to placebo.43   The A1C reduction in older 
adults (aged ≥ 65 years) was numerically smaller than in 
younger patients (aged < 65 years).47  It is suggested that 
reduced renal function in patients aged ≥ 65 years may explain 
this finding because A1C reductions were comparable between 
older and younger patients when controlling for eGFR.47
Canagliflozin (100mg and 300mg) significantly reduced A1C 
compared with placebo in adults with T2DM and Stage 3 
chronic kidney disease (CKD; eGFR ≥ 30 to < 50mL/min/ 
173 m2) (Table 1).44  Numerical changes in body weight, SBP, 
and HDL-C favored canagliflozin, but statistical comparisons 
were not performed. Analysis of pooled data from four 
randomized, placebo-controlled phase 3 studies showed 
statistically significant reductions in A1C with canagliflozin 
100mg and 300mg in patients with Stage 3a (eGFR ≥ 45 to 




Safety results of phase 3 trials of canagliflozin are summarized 
in Table 1 (pages 12-17). In a pooled analysis of four phase 3 
trials, the most commonly reported AEs deemed related to 
canagliflozin are GMIs and UTIs.46 
GMIs were reported in 3.2% of women with placebo and 
in 10.4% and 11.4% with canagliflozin 100mg and 300mg, 
respectively.46  GMIs also occurred in men receiving 
canagliflozin, although less often than in women (0.6% 
with placebo vs. 4.2% and 3.7% with canagliflozin 100mg and 
300mg, respectively).46  In both men and women, GMIs were 
mild or moderate in intensity and resolved with standard 
antifungal therapy.46 
Canagliflozin therapy resulted in a slight increase in UTIs 
relative to placebo (4.0% with placebo vs. 5.9% and 4.3% with 
canagliflozin 100mg and 300mg, respectively), with low rates of 
serious UTIs and no increased incidence in upper UTIs.46 AEs 
associated with osmotic diuresis (0.8% with placebo vs. 6.7% 
and 5.6% with canagliflozin 100mg and 300mg, respectively) 
and volume depletion (1.1% with placebo vs. 1.2% and 1.3% 
with canagliflozin 100mg and 300mg, respectively) were also 
reported.46 
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h  Statistical analysis not performed.
i  p<0.025 vs. PBO.
j  p<0.05 vs. PBO, difference vs. baseline.
A1C, glycated hemoglobin A1c  ;  CANA, canagliflozin;  CKD, chronic kidney disease;  F, females;  GLIM, glimepiride;  GMIs, genital mycotic 
infections;  HDL-C, high-density lipoprotein cholesterol;  M, males;  MET, metformin;  NR, not recorded;  PBO, placebo;  PIO, pioglitazone; SBP, 
systolic blood pressure;  SITA, sitagliptin;  SU, sulfonylurea;  UTIs, urinary tract infections.
The occurrence of serious AEs was similar across treatment 
groups (< 4%), and treatment discontinuation was low overall 
with no discernible relation to dose (3.1% in the placebo 
group vs. 4.3% and 3.6% with canagliflozin 100mg and 300mg, 
respectively).46 
The incidence of hypoglycemia was similar between 
canagliflozin monotherapy and placebo when patients were 
not on background therapy, including a sulfonylurea (2.2% 
with placebo vs. 3.8% and 4.3% with canagliflozin 100mg and 
300mg, respectively). However, it occurs more frequently, as 
expected, with canagliflozin dual therapy (with a sulfonylurea) 
relative to placebo (15.4% with placebo vs. 27.4% and 30.1% 
with canagliflozin 100mg and 300mg, respectively). This is 
consistent with the pattern seen when an AHA with a low risk 
of hypoglycemia is given to patients on an AHA with a high 
risk of hypoglycemia (e.g. sulfonylurea, insulin).46 
DAPAGLIFLOZIN:
EFFICACY AND CLINICAL BENEFITS
Table 2 (pages 18-21) summarizes results of phase 3 trials of 
dapagliflozin.30, 49-56 Compared with placebo, dapagliflozin 
5mg and 10mg significantly reduced A1C as monotherapy,30 
and as dual therapy (added to metformin, glimepiride, 
pioglitazone, or insulin therapy).50, 52-54  As triple therapy 
(added to metformin plus a sulfonylurea), dapagliflozin 
10mg resulted in significantly greater A1C reduction relative 
to placebo; dapagliflozin 5mg was not evaluated.55  As dual 
therapy (added to metformin), dapagliflozin (mean dose 
9.2mg) compared with glipizide (mean dose 16.4mg) was 
statistically non-inferior in A1C reduction.51
Body weight changes with dapagliflozin monotherapy (5mg 
or 10mg) did not differ significantly from those observed 
with placebo after 24 weeks.30  An extension of this study, 
comparing dapagliflozin 10mg monotherapy with placebo 
plus low-dose metformin therapy (with metformin added 
to placebo after 24 weeks) did show a significant difference 
in body weight change at 102 weeks.49   Adding dapagliflozin 
5mg or 10mg to metformin, glimepiride, pioglitazone, or 
insulin therapy resulted in significantly greater body weight 
reduction from baseline compared with placebo.50, 52-54 
A 24-week study of dapagliflozin concluded that the weight 
loss observed (difference from placebo in change from 
baseline: 2.1kg) was due to decreases in fat mass, visceral 
adipose tissue, and subcutaneous adipose tissue. Reduction 
in fat mass (rather than lean body mass) accounted for 
two-thirds of the weight loss.57
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Efficacy and Safety of DAPA in Randomized, Double-Blind Phase 3 Trials of Patients With Type 2 Diabetes Mellitus
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Combination Therapy (Continued)
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a Adjusted mean change from baseline value 
(with standard error in parentheses where provided).
b Seated SBP. 
c p<0.001 vs. comparator, difference vs. baseline. 
d p<0.0001 vs. PBO or comparator, difference vs. baseline. 
e p=0.0136 vs. PBO, difference vs. baseline.
f p=0.0067 vs. PBO, difference vs. baseline.
g Non-inferiority established.
h p=0.0091 vs. PBO.
i p=0.0007 vs. PBO.
j p=0.025 vs. PBO.
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A1C, glycated hemoglobin A1c  ; DAPA, dapagliflozin;  F, females;  GLIM, glimepiride;  GMIs, genital mycotic infections;  
HDL-C, high-density lipoprotein cholesterol;  INS, insulin; M, males;  MET, metformin;  NR, not reported;  PBO, placebo;  
PIO, pioglitazone;  SBP, systolic blood pressure;  SU, sulfonylurea;  UTIs, urinary tract infections.
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EFFICACY AND CLINICAL BENEFITS - DAPAGLIFOZIN
Significantly greater SBP reductions from baseline have been 
reported with dapagliflozin than with metformin alone50 or 
metformin plus a sulfonylurea.55  A separate study reported 
a non-significant increase in SBP with dapagliflozin 10mg 
compared with placebo plus low-dose metformin, which 
may have been due to the fact that this study population had 
a relatively normal SBP at baseline.49  Although changes in 
HDL-C have not been reported by treatment arm in most 
of the dapagliflozin phase 3 trials, an analysis of pooled 
data from four phase 3 studies reported consistent increases 
in HDL-C with dapagliflozin.58  Dapagliflozin has been 
associated with small increases in LDL-C (mean percentage 
change from baseline at week 24 ranged from 0.6% to 2.7% 
with dapagliflozin 2.5 mg, 5 mg, and 10 mg vs. −1.9% with 
placebo).59 
Lowering of A1C with dapagliflozin 5 mg and 10 mg in 
T2DM patients with moderate renal impairment did not differ 
significantly from placebo at 24 weeks.56
DAPAGLIFLOZIN:
SAFETY
Safety results of phase 3 trials of dapagliflozin are summarized 
in Table 2 (pages 18-21). Separate analyses of pooled data have 
evaluated the incidence of GMIs and UTIs in 12 randomized, 
placebo-controlled, phase 2b/3 trials of dapagliflozin 
(n=4,545).60, 61 These analyses included patients who had 
received placebo or dapagliflozin as monotherapy or as 
add-on therapy to metformin, insulin, a sulfonylurea, or a 
thiazolidinedione for 12-24 weeks. The incidence of diagnosed 
GMIs in women was 1.5% with placebo, and 8.4% and 6.9% 
with dapagliflozin 5mg and 10mg, respectively. In men, the 
incidence of GMIs was 0.1% with placebo, and 1.2% and 
1.2% with dapagliflozin 5 mg and 10 mg, respectively.  The 
incidence of diagnosed UTIs was 3.7% with placebo, and 5.7% 
and 4.3% with dapagliflozin 5 mg and 10 mg, respectively.61 
GMIs and UTIs were generally mild to moderate in severity 
and responded to conventional therapy.59
Various terms have been used to report hypotension in 
dapagliflozin trials; in some, hypotension is combined 
with hypovolemia and dehydration. In at least one trial, 
no incidents of orthostatic hypotension were reported.53  
Other studies have reported either no change from baseline 
in the proportion of patients experiencing orthostatic 
hypotension51 or few hypotensive events across treatment 
groups.30  A safety summary of dapagliflozin reported 
incidences of 0.6% and 0.8% for dapagliflozin 5 mg and 
10mg, respectively, vs. 0.4% in the placebo group for events 
defined as volume depletion (hypotension, dehydration, and 
hypovolemia).59  Of note, there is currently no data available 
on volume depletion-related AEs with dapagliflozin in patients 
with high cardiovascular risk. Patients using loop diuretics, 
those with eGFR < 60 mL/min/1.73 m2, or those aged 
≥ 65 years are at increased risk of these AEs.62   Dapagliflozin 
trials did not address urinary frequency or urinary volume 
as AEs. 
Use of dapagliflozin infrequently resulted in hypoglycemia; 
however, when used in combination with glimepiride52 or 
insulin,63 hypoglycemia incidence was increased compared 
with placebo.64 
EMPAGLIFLOZIN:
EFFICACY AND CLINICAL BENEFITS
Table 3 (pages 24-27) summarizes results of phase 3 trials 
of empagliflozin.37, 65-70  A1C reduction with empagliflozin 
10 mg or 25 mg was statistically superior to that observed with 
placebo when given as monotherapy37 and in combination with 
metformin,66 metformin plus a sulfonylurea,65 pioglitazone, 
or pioglitazone plus metformin,68 or multi-dose insulin with 
or without metformin.69  As add-on therapy to metformin, 
empagliflozin 25 mg has been shown to be statistically superior 
to glimepiride (mean maximum titrated dose 2.71 mg/day) 
in a 104-week study.67  A1C reduction with empagliflozin 
10 mg and 25 mg was similar to A1C reduction with sitagliptin 
100 mg.37 
Statistically significant reductions in body weight and SBP 
(relative to placebo) have been observed with empagliflozin 
10 mg and 25 mg as monotherapy,37 in combination with 
metformin,66  with metformin plus a sulfonylurea,65 and with 
pioglitazone or pioglitazone plus metformin.68   Empagliflozin 
10 mg and 25 mg added to multi-dose insulin with or without 
metformin resulted in a statistically significant reduction 
in body weight and a non-significant reduction in SBP.69  
In combination with metformin, empagliflozin 25 mg resulted 
in statistically significant reductions in body weight and SBP 
compared with glimepiride.67 
Empagliflozin added to metformin plus pioglitazone 
has been associated with small increases in HDL-C in 
placebo-controlled studies: 0.06 mmol/L (2.32 mg/dL) with 
empagliflozin 10 mg and 0.03 mmol/L (1.16 mg/dL) with 
empagliflozin 25 mg.68   With metformin only, increases 
in HDL-C of 0.08 mmol/L (3.09 mg/dL) and 0.06 mmol/L 
(2.32 mg/dL) with empagliflozin 10 mg and 25 mg, respectively, 
relative to placebo were observed.66   Empagliflozin as 
add-on to metformin has been reported to result in small 
increases in LDL-C (adjusted mean increase 0.15 mmol/L 
[5.80 mg/dL] with each dose) relative to placebo (0.03 mmol/L 
[1.16 mg/dL]).66 
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Empagliflozin 25 mg resulted in an adjusted mean change 
in A1C from baseline of −0.42% relative to placebo at week 
24 in patients with eGFR ≥ 30 to < 60 mL/min/1.73 m2.70 
In patients with Stage 2 and Stage 3 CKD, empagliflozin 
resulted in significant reductions in A1C, body weight, and 
SBP compared with placebo after 52 weeks, while in patients 




Safety results of phase 3 trials of empagliflozin are summarized 
in Table 3 (pages 24-27).  Based on pooled analyses, the most 
frequently occurring AEs with empagliflozin are UTIs (7.6% 
with placebo vs. 9.3% and 7.6% with empagliflozin 10 mg 
and 25 mg, respectively) and GMIs (in female patients: 1.5% 
with placebo vs. 5.4% and 6.4% with empagliflozin 10 mg 
and 25 mg, respectively).22  AEs related to osmotic diuresis 
and volume depletion have been evaluated from pooled 
data from phase 1, 2, and 3 studies in > 11,000 patients.71 
In that analysis, the overall incidence of volume depletion 
events was 1.4% with empagliflozin 10mg and 1.5% with 
empagliflozin 25 mg vs. 1.4% with placebo.  The incidence 
of these events was higher in patients aged ≥ 75 years, those 
with eGFR < 30 mL/min/1.73m2, and those also receiving 
diuretic therapy.71  Empagliflozin therapy is associated with 
hypoglycemia when used with another AHA that has a high 
risk of hypoglycemia.65,68,69
IMPLICATIONS FOR PRACTICE 
The successful management of patients with T2DM requires 
holistic care, addressing measures beyond A1C reduction. The 
ADA/European Association for the Study of Diabetes and the 
AACE recommend considering the impact on body weight 
and risk of hypoglycemia, as well as tolerability and cost, when 
selecting second- and third-line treatment regimens.4, 5, 72 
Patient types that might be considered particularly good 
candidates for SGLT2 inhibitor therapy include overweight 
or obese individuals and those with high levels of insulin 
resistance or low levels of pancreatic beta-cell function. 
Clinicians may wish to exercise caution before prescribing 
SGLT2 inhibitor therapy for those with risk factors for 
volume depletion-related AEs and who also face elevated risk 
for falling or injury due to falls (e.g. osteoporosis, Parkinson 
disease, dementia). 
SGLT2 inhibitors offer a novel mechanism of glycemic control 
by reducing renal glucose reabsorption and increasing UGE. 
Use of SGLT2 inhibitors offers the additional benefits of 
reducing blood pressure and body weight, with a low risk of 
hypoglycemia. The three SGLT2 inhibitors available in the 
United States, canagliflozin, dapagliflozin, and empagliflozin, 
are oral once-daily medications that improve glycemic control 
with a convenient dosing schedule. The most common 
side-effects are GMIs, UTIs, and increased urination. GMIs 
and UTIs are generally mild to moderate in severity, respond 
well to conventional treatment, and rarely result in treatment 
discontinuation. Studies are ongoing to provide further 
information on the long-term efficacy and safety of SGLT2 
inhibitors and data will become available in the coming years. 
As SGLT2 inhibitors offer an insulin-independent mode of 
action, they can be used in patients at all stages of type 2 
diabetes.26-28 
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3 M,   4 F
1 M,   9 F
0 M,   0 F
2 M,  15 F
1 M,  13 F







0.9 M,   4.5 F
0.9 M,   3.9 F
0.9 M,   0.9 F
2.7 M,   18.0 F
0 M,   17.5 F




0.8 M, 7.6 F
0.8 M,   9.7 F
0 M,   0 F
0 M, 12.0 F
0.8 M, 11.8 F
2.6 M, 7.7 F
14
13
9 M,   15 F
1 M,   3 F
7 M,   22 F




7.2 M,   9.8 F
1.2 M,   6.0 F
1.4 M,   3.3 F
3.6 M,  30.5 F
2.4 M,  21.7 F
8.2 M,  22.8 F
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Combination Therapy (Continued)
MDI INS ± 

































































































a Adjusted mean change from baseline value 
(with standard error in parentheses where provided).
b p<0.0001 for difference vs. PBO or comparator.
c p=0.0231 for difference vs. PBO.
d p=0.0028 for difference vs. PBO.
e p≤0.001 for difference vs. PBO.
f p=0.005 for difference vs. PBO.
g p=0.032 for difference vs. PBO.
h p=0.0153 (superiority) vs. GLIM.
i p=0.0006 for difference vs. PBO.
j p=0.0023 for difference vs. PBO.









1.0 M,   7.9 F
8.3 M,   10.5 F
1.3 M,   1.8 F
5.2 M,   27.0 F
3.6 M,   24.8 F





10.0 M,   2.6 F
0 M,   13.9 F
3.6 M,  10.3 F
8.3 M,   23.7 F
3.3 M,   19.4 F
8.9 M,   25.6 F
16.6
15.5
1.9 M,   3.8 F
0.9 M,   1.2 F
5.6 M,   31.3 F
3.8 M,   30.9 F
18.9
8.1
0 M,   6.3 F
0 M,   0 F
9.5 M,   31.3 F
0 M,   16.7 F 
A1C, glycated hemoglobin A1c  ;  CKD, chronic kidney disease;  EMPA, empagliflozin;  F, females;  GLIM, glimepiride;  GMIs, genital 
mycotic infections;  INS, insulin;  M, males;  MDI, multiple daily injections;  MET, metformin;  open-label; PBO, placebo;  
PIO, pioglitazone;  SBP, systolic blood pressure;  SU, sulfonylurea;  UTIs, urinary tract infections.
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